WEP Clinical (WEP) and Nabriva Therapeutics (Nabriva) are pleased to announce the expansion of the XENLETA® (lefamulin) Named Patient Program (NPP) into Australia, New Zealand, Singapore and South Africa. NPP is designed to ensure [...]

WEP Clinical (WEP) announced today that it has extended its partnership with BTG Specialty Pharmaceuticals (BTG), a division of Boston Scientific. Last year, WEP announced it would be partnering with BTG to supply the [...]